WANDA BEARING
920002
CG MED EQUIP.
838810
SUZHOUBEARING
430418
4
COCYBER
835207
5
Guangdong Create Century Intelligent Equipment Group Corporation
300083
US Stock MarketDetailed Quotes
FBLG FibroBiologics
- 1.140
- +0.090+8.57%
Close Feb 26 16:00 ET
- 1.130
- -0.010-0.88%
Post 16:41 ET
42.34MMarket Cap-2.18P/E (TTM)
1.210High1.050Low246.94KVolume1.060Open1.050Pre Close279.01KTurnover0.90%Turnover RatioLossP/E (Static)37.14MShares13.59052wk High15.41P/B31.17MFloat Cap0.98452wk Low--Dividend TTM27.35MShs Float55.000Historical High--Div YieldTTM15.24%Amplitude0.984Historical Low1.129Avg Price1Lot Size
Trending Stocks
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call
FibroBiologics Stock Forum
i liking. I like it a lot. you are moving to the top of ⌚️ might enter you Friday night for cheap. 🤫🫡😈
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER...
FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing
Monday, 30th December at 4:30 pm
HOUSTON, Dec. 30, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it has closed the second $5...
Yorkville agreed to advance to FibroBiologics the first $15 million available und...
FibroBiologics Announces $25 Million Financing
Monday, 23rd December at 7:55 am
HOUSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it has entered into a Standby Equity Purchase Agreement (th...
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics
FibroBiologics (Nasdaq: FBLG) has filed a patent application for methods using fibroblasts and Tissue Factor-expressing cells to prevent IBMIR-mediated blood clotting in cell therapy treatments. The technology aims to address a major challenge in cell therapy by reducing inflammatory and coagulative...
No comment yet